The Global Market for Human Embryonic Stem Cell (hESC) Research is Projected to Reach US$2 Billion by 2022
Limitations with Existing Treatment Modalities &
the Need for Radical Therapies for Human Disorders Drive Interest in Human
Embryonic Stem Cell (hESC) Research, According to a New Report by Global Industry Analysts, Inc.
GIA launches comprehensive
analysis of industry segments, trends, growth drivers, market size, share and
demand forecasts on the global Human Embryonic Stem Cell (hESC) Research market.
The
global market for Human Embryonic Stem Cell (hESC) Research is projected to
reach US$2 billion by 2022, driven by the pressing need to revolutionize
healthcare; find biological solutions to diseases that have so far defeated the
expertise of modern medical care; and the ensuing need for innovation in stem
cell research.
Aging population and
concurrent increase in degenerative ailments are major reasons for rising
healthcare expenditures across the world. It is in this scenario that
regenerative medicine, and stem cell therapies in particular, emerged in
biotechnology arena. Human embryonic stem cell (hESC), represent a type of stem
cells that are extracted from an embryo when it is at blastocyst stage.
Embryonic stem cells represent building blocks for around 260 different cell
types in human body, which can be differentiated into virtually any type of
cells including nerve cells and muscle cells, providing ample prospects for use
in development of therapies for a range of diseases. Research work in this area
revolves around guiding these extracted embryonic stem cells in-vitro to
differentiate into specific cell types, which can subsequently be transplanted
into human body to treat targeted diseases. Human embryonic stem cells are also
used in investigational studies of early human development, genetic diseases
and toxicology testing. The global human embryonic stem cell market, in terms
of research investments, is slated to witness a significant growth over the
forecast period on account of increasing incidences of blood, genetic and
immunity related disorders. Aging population, growing prevalence of diseases,
increasing exposure to hazardous elements, growing genetic mutations, changing
lifestyle and gaps in existing therapies are some of the factors driving
research investments in this space.
Despite the promise that
hESC exudes in the area of regenerative medicine, research in this space was
plagued by several hurdles that restrained growth in the market. These includes
issues such as cell rejection by host’s immune system as a result of
histo-incompatibility and potential chances for tumor development, as well as
ethical issues revolving around hESC sourcing, regulations and government
support. Growing popularity of adult induced pluripotent stem cells as an
alternative to hESC and patenting issues related to hESC are some of the other
factors restraining growth in the market. The US ban on funding hESC research
for a sustained period and limited funding in other parts of the world delayed
advancements in stem cell medicine. However, the lifting of the ban, continuing
gaps in existing therapeutics industry, elimination of concerns over hESCs
causing teratomas have helped increase in funding. hESCs find use in clinical
applications and drug toxicology testing. hESC is at present being studied for
treatments in a range of areas including cardiology, dental, lung diseases,
kidney diseases, neurodegenerative conditions
and liver diseases among others. Research advances such as isolation of
viable haploid
hESC lines that improved further insights into basic biology are expected
to drive research investments in the following years.
As stated by the new
market research report on Human
Embryonic Stem Cell (hESC) Research, the United States represents the
largest market worldwide, supported by the rise in cardiac, genetic, malignant
and neurological disorders; dire need for more novel and effective therapies;
growing awareness over the importance of hESC research; and presence of
excellent healthcare infrastructure and government initiatives. Emerging markets
such as Asia-Pacific are also expected to witness sizable growth in investments
in the years ahead, driven in part by increasing investments by venture
capitalists; and rise in the number of successful projects supported by the
implementation of guidelines governing best practices of research and
development in this space; and co-ordination between regulatory agencies,
therapy developers, and drug safety scientists; and developing of technologies
to process and manufacture stem cells and their derivatives.
Major players covered in
the report include Astellas Institute of Regenerative Medicine, Asterias
Biotherapeutics, Inc., BD Biosciences, Cell Cure Neurosciences Ltd., Cellular
Dynamics International, GE Healthcare, PerkinElmer, Inc., Reliance Life
Sciences Ltd., Research & Diagnostics Systems, Inc., SABiosciences Corp.,
STEMCELL Technologies, Inc., Stemina Biomarker Discovery, Inc., Takara Bio,
Inc., TATAA Biocenter AB, Thermo Fisher Scientific, Inc., UK Stem Cell Bank and
ViaCyte, Inc. among others.
The
research report titled “Human
Embryonic Stem Cell (hESC) Research: A Global Strategic Business Report”
announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, mergers,
acquisitions and other strategic industry activities of global companies. The
report provides market estimates and projections for Human Embryonic Stem Cell
(hESC) Research in value terms for the period 2014-2022.
Global
Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights
Reserved.
Comments
Post a Comment